STOCK TITAN

SCYNEXIS (SCYX) SEC Filings, Jun 26-30, 2025

SCYX NASDAQ

SCYNEXIS, Inc.’s SEC filings document a biotechnology company with clinical-stage development programs in rare kidney disease and antifungal medicine. Its reports and current-event filings cover the acquired PXL-770, now SCY-770, AMPK activator assets for ADPKD; SCY-247 clinical and regulatory disclosures; and license arrangements involving ibrexafungerp and BREXAFEMME® with GSK.

SCYNEXIS filings also describe common-stock capitalization, material agreements, risk factors, operating and financial results, and Nasdaq-listed common stock. Proxy materials and Form 8-K reports cover shareholder voting matters, governance, board composition, executive compensation, auditor ratification, and proposed certificate-amendment matters affecting the company’s equity structure.

Form 4
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
insider
-
Form 4
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
insider
-
Rhea-AI Summary

SCYNEXIS (Nasdaq: SCYX) disclosed receipt of a Nasdaq bid-price deficiency notice on 20 Jun 2025 after its shares closed below $1.00 for 30 straight sessions.

The company has 180 days (until 17 Dec 2025) to lift the bid to at least $1 for 10 consecutive trading days. If unsuccessful, it may transfer to the Nasdaq Capital Market for another 180-day cure or face delisting, subject to appeal.

  • Current Nasdaq Global Market listing remains unaffected.
  • Management can pursue a reverse stock split or other actions to regain compliance.
  • The notice heightens liquidity and funding risk and could deter institutional holders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.14%
Tags
current report

FAQ

How many SCYNEXIS (SCYX) SEC filings are available on StockTitan?

StockTitan tracks 63 SEC filings for SCYNEXIS (SCYX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for SCYNEXIS (SCYX)?

The most recent SEC filing for SCYNEXIS (SCYX) was filed on November 16, 2026.